Nasdaq

Mithra Pharmaceuticals: INFORMATION ON THE TOTAL NUMBER OF VOTING RIGHTS (DENOMINATOR)

27-06-2017

Information on the total number of voting rights (denominator)

Liège, Belgium
,
27 June 2017 [
5:45 pm CET
]
- Regulated information -
In accordance with article 15 of the Act of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 3,112,975 new shares on 23 June 2017 in the framework of the private placement announced by press release of 21 June 2017:

  • Share capital: €25,068,992.13

            Total number of securities carrying voting rights: 34,242,731 (all ordinary shares)

  • Total number of voting rights (= denominator): 34,242,731 (all relating to ordinary shares)
  • Number of rights to subscribe securities carrying voting rights not yet issued:

            1,089 warrants issues on 2 March 2015, entitling their holders to subscribe for a total number of 1,796,850 securities carrying voting rights (all ordinary shares)

For more information, please contact:

Sofie Van Gijsel, IRO


investorrelations@mithra.com


svangijsel@mithra.com


+32 485 19 14 15


Consilium Strategic Communications



Jonathan Birt, Sue Stuart, Philippa Gardner, Hendrik Thys, Cameron Standage




mithra@consilium-comms.com




+44 2 037 095 700

About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women's Health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive Estelle® and next-generation hormone therapy Donesta® - are built on Mithra's unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at:
www.mithra.com

Important information:

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's mailing list, visit
investors.mithra.com



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Mithra Pharmaceuticals via GlobeNewswire

HUG#2116055

Interstitiel mediset